CJC-1295 vs Ipamorelin vs Semaglutide

A three-way comparison to help you find the right peptide for your research goals.

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.

Full details →

Semaglutide

Semaglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) with a 94% sequence homology to native GLP-1. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Semaglutide has an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It is the most widely prescribed GLP-1 medication globally, with over 25 million Americans expected to be on GLP-1 therapy by 2030.

Full details →

Side-by-Side Comparison

Aspect	CJC-1295	Ipamorelin	Semaglutide
Dose Range	1 mg–2 mg	100 mcg–300 mcg	250 mcg–2.4 mg
Frequency	Less than daily	2x daily	Less than daily
Cycle Length	8–12 weeks	8–12 weeks	16–52 weeks
Route	subcutaneous	subcutaneous	subcutaneous or oral
Mechanism	CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.	Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones.	Semaglutide binds to and activates the GLP-1 receptor, a G-protein coupled receptor expressed in pancreatic beta cells, the hypothalamus, and the gastrointestinal tract. This triggers multiple downstream effects: (1) glucose-dependent insulin secretion from pancreatic beta cells, (2) suppression of glucagon release from alpha cells, (3) delayed gastric emptying, slowing nutrient absorption, (4) central appetite suppression via hypothalamic GLP-1 receptors, reducing hunger and increasing satiety. The peptide features a C-18 fatty diacid moiety attached via a linker to Lys26, enabling non-covalent albumin binding that protects against DPP-4 degradation and renal clearance.
Typical Dosage	CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.	Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295.	For weight management (Wegovy): start at 0.25 mg weekly for 4 weeks, escalate to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg weekly. Each escalation lasts 4 weeks. Maintenance dose is 2.4 mg weekly. For type 2 diabetes (Ozempic): start at 0.25 mg weekly for 4 weeks, increase to 0.5 mg. May increase to 1 mg, then 2 mg if additional glycemic control is needed. Oral semaglutide (Rybelsus): 3 mg daily for 30 days, then 7 mg daily. May increase to 14 mg daily. Oral Wegovy: 3 mg daily for 4 weeks, escalate to 7 mg, 14 mg, and 25 mg daily. Take on empty stomach with no more than 4 oz of water, 30 minutes before food.
Administration	Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.	Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides.	Injectable: subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Store pens refrigerated (36-46°F) before first use; after first use, store at room temperature or refrigerated for up to 56 days. Oral: take on an empty stomach with a sip of plain water (no more than 4 oz). Wait at least 30 minutes before eating, drinking, or taking other oral medications. Do not split, crush, or chew tablets.
Side Effects	Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.	Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially.	Very common (>10%): nausea (up to 44%), diarrhea, vomiting, constipation, abdominal pain. These are typically mild-to-moderate and decrease over time with dose escalation. Common (1-10%): headache, fatigue, dyspepsia, dizziness, bloating, flatulence, GERD, gastroenteritis. Notable: 'Ozempic face' (facial volume loss due to rapid weight loss), hair loss (telogen effluvium, reported in 25-33% of users in some studies), injection site reactions.
Best For	Muscle Growth Fat Loss Sleep Quality	Muscle Growth Fat Loss Recovery & Healing Sleep Quality	Weight Loss Diabetes Management Cardiovascular Health